I recall at the meeting that it was mentioned that they were working through the clinical trial payment and that because it was contracted it should be payed. However it did not sound like a definite.
Sure would help with the short term liabilities
Sure is a big loss for the year, they are either very confident that the money already spent will lead to growth or went to hard to quickly.
AT the EGM Craig mentioned that after the previous quarterly the market was shocked with low cash but that it was being managed extremely efficiently and was always in control Hopefully this is the case going forward. Also mentioned that once embargo is finished looking forward going from a regulatory process which has consumed a lot of time to focusing on the marketing process.
When the IPO funds are raised i think the market will want to see results quickly once Pulse is launched.
